Dr. Steven Theriault reports

CYTOPHAGE ANNOUNCES APPOINTMENT OF JAMES KINLEY AS CHIEF FINANCIAL OFFICER

Cytophage Technologies Ltd. has appointed James Kinley, CPA, CA, as chief financial officer (CFO) of the company.

Mr. Kinley, based in Winnipeg, brings extensive experience in the biotech industry, having served as a CFO to several publicly listed health care companies over the past 15 years, including his current engagement as CFO to Algernon Health Inc. (Canadian Securities Exchange: AGN). He will work with management and the board of directors to ensure continued compliance with the company's financial reporting obligations and the requirements of applicable securities regulators and the TSX Venture Exchange. As a fractional CFO, the company will also be able to benefit from cost savings in the appointment of Mr. Kinley.

Mr. Kinley replaces Julius Kalcevich who has been the company's CFO since July, 2023. Mr. Kalcevich was brought on to take the company public through a reverse takeover (RTO) and lead several financing efforts. Mr. Kalcevich has agreed to assist with an orderly transition and will work closely with Mr. Kinley to support continuity of financial oversight, reporting and public company compliance during the transition period. Mr. Kalcevich will remain available to the company as an ad-hoc independent consultant.

Cytophage chief executive officer Dr. Steven Theriault and the board of directors would like to thank Mr. Kalcevich for his considerable contributions to Cytophage during a period of continued corporate development, financing activity and advancement of its bacteriophage technology platform.

About Cytophage Technologies Ltd.

Cytophage Technologies is a pioneering biotechnology company dedicated to bacteriophage research, product development and commercialization.

Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular or organism-level defences. They are nature's version of antibiotics.

Cytophage is improving bacteria's natural predators with environmental as well as genetic modifications to bring safe and toxin-free killer solutions to large addressable markets with an initial focus on animal health which offers a fast track to near-term revenue. As a leading bacteriophage manufacturer in Canada and powered by a large library of phage strains, Cytophage is committed to addressing the global challenge of antibiotic resistance (AMR). The WHO predicts that AMR will be the leading cause of human mortality by 2050. Many countries have already banned or limited preventative antibiotic use in animal production including 27 European Union countries, United States, Canada, Brazil, Bangladesh, India and Mexico. In addition to that, consumers all over the world are demanding organic and antibiotic-free products.

Cytophage is using a derisked and patented technology to advance innovative and cost-competitive products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health and food security.

We seek Safe Harbor.